Eye on FDA: What We Didn’t Hear at the FDA Part 15 Meeting on Social Media


Eye on FDA: What We Didn’t Hear at the FDA Part 15 Meeting on Social Media

We heard from far too few pharma companies, and far too many bloggers.

What was missing? What anyone should be doing in the meantime, what’s the process going forward, and what (if anything) is going on in Europe.

Information and Links

Join the fray by commenting, tracking what others have to say, or linking to it from your blog.


Other Posts

Write a Comment

Take a moment to comment and tell us what you think. Some basic HTML is allowed for formatting.

Reader Comments

Be the first to leave a comment!